Form 4: Allakos CFO Radford Baird Disposes of Shares and Options in Merger with Concentra Biosciences

Allakos CFO Radford Baird disposed of common stock and stock options following the merger agreement with Concentra Biosciences.

Summary

• On May 15, 2025, Allakos Inc.'s Chief Financial Officer, Radford Harlan Baird, reported changes in beneficial ownership of the company's securities.
• Baird disposed of 163,426 shares of common stock at a price of $0.33 per share, as well as stock options to purchase 27,600 and 194,144 shares, all in connection with the merger agreement with Concentra Biosciences.
• The transactions were executed pursuant to the terms of the merger agreement dated April 1, 2025, between Allakos, Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc.
• Following the reported transactions, Baird's direct ownership of common stock and derivative securities is now zero.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports transactions related to a merger, which is neither inherently positive nor negative.

Future Outlook

The document does not contain specific forward-looking statements beyond the implications of the merger agreement.

Industry Context

This announcement reflects the impact of a merger on the holdings of a key executive, which is a common occurrence during such corporate events. It indicates the executive's alignment with the terms of the merger agreement.

Stakeholder Impact

• Shareholders received $0.33 per share as part of the merger agreement.
• The cancellation of stock options impacts the CFO's equity compensation.

Key Dates

Keywords

Allakos, Radford Baird, Concentra Biosciences, Merger, Form 4, Beneficial Ownership, Stock Options, Common Stock, CFO